TECHNICAL ANALYSIS
REGN
Regeneron Pharmaceuticals
TECHNICAL RATING
TECHNICAL SCORE
83 / 100
Summary
Price sits about 5.0% above the 20-day MA (769.03), 2.1% above the 50-day MA (791.44), and 9.9% above the 200-day MA (734.8), and the 50/200-day crossover is a Golden cross. Momentum is constructive: MACD (9.056) is above its signal (2.497) and the RSI(14) is 58.8 in the neutral-constructive band, so momentum is confirming the upward trend. The stock is trading inside the Bollinger bands while volume is running below its 20-day average, which reduces conviction behind recent gains. Key things to watch are whether volume picks up to support higher prices or if price falls back toward the 20/50-day moving averages, which would change the setup.
Price & Moving Averages
Volume
RSI (14)
MACD (12/26/9)
Formula & Methodology
Short-term trendPrice vs. 20-day moving average (weight 10%)
Intermediate trendPrice vs. 50-day moving average (weight 15%)
Long-term regimePrice vs. 200-day moving average (weight 25%)
Cross state50/200 Golden or Death cross (weight 10%)
Momentum + trendMACD 12/26/9 vs signal line (weight 15%)
Momentum bandsRSI (14) state (weight 10%)
VolatilityBollinger-band position (weight 5%)
ConfirmationVolume vs 20-day average (weight 10%)
Rating ruleFormula: the Technical Score is a weighted composite of eight inputs. Trend inputs — price vs. the 20-day (10%), 50-day (15%), and 200-day (25%) moving averages, and the 50/200 Golden or Death cross state (10%) — carry roughly 60% of the weight. Momentum inputs — MACD (12/26/9) vs. its signal line (15%) and RSI (14) state (10%) — carry 25%. Bollinger-band position (5%) and volume vs. the 20-day average (10%) round out the remainder. Each input contributes +1, 0, or -1, weights are re-normalized when a component is unavailable, and the weighted sum is thresholded at +/-0.45 to Bullish, Neutral, or Bearish.
Data Source
Market data sourced from Tiingo. End-of-day prices and volume power the charts and indicators (MA20/50/200, RSI, MACD, Bollinger Bands, Volume) on this page. This page is informational analysis, not investment advice. See Financial Disclaimer.